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ABSTRACT 
Background. Peritoneal adhesions are a common complication after abdominal surgery. They cause small 
bowel obstruction, female infertility and chronic abdominal pain. Peritoneal adhesions also hamper uniform 
drug distribution in the peritoneal cavity, thereby reducing the efficacy of intraperitoneal chemotherapy after 
cytoreductive surgery.  
Aim. The goal of this study was to develop a formulation that prevents peritoneal adhesions, evenly 
distributes in the abdominal cavity, and simultaneously extends residence time and improves local drug 
concentration. This report describes the formulation and characterization of genipin-crosslinked gelatin 
microspheres (GP-MS).  
Methods and results. Spheroid gelatin microspheres were prepared by an emulsification solvent extraction 
method. A higher degree of crosslinking was obtained by increasing genipin concentration and crosslinking 
time. The degree of crosslinking allowed to tailor the degradation rate of GP-MS, hence their residence time. 
GP-MS did not affect cell viability. In vivo experiments showed excellent GP-MS biocompatibility and 
degradation characteristics. GP-MS were distributed evenly throughout the abdominal cavity. Adhesions 
were induced in Balb/c mice by application of an abraded peritoneal wall-cecum model. GP-MS-treated mice 
developed significantly less postsurgical adhesions compared to saline and Hyalobarrier® group. 
Histopathological examination showed a decrease of peritoneal inflammation over time in GP-MS-treated 
mice with complete recovery of peritoneal wounds post-operative day 14.  
Conclusion. GP-MS are a promising strategy to prevent postoperative peritoneal adhesions and improve 
efficacy of postoperative intraperitoneal chemotherapy.  
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1. Introduction 
 Peritoneal adhesions are defined as pathological attachments between tissues and organs, 
usually between the omentum, bowel loops and the abdominal wall. They can be classified as congenital 
or acquired[1]–[3]. The majority of adhesions is acquired and can be subdivided according to their 
inflammatory or postsurgical etiology. Inflammatory adhesions result from the inflammatory response 
of the peritoneum during intra-abdominal inflammatory processes such as acute appendicitis, pelvic 
inflammatory disease and exposure to intestinal contents[1]–[3]. Postsurgical adhesions develop when 
injured tissue fuse together to form scar tissue[1]–[4]. The reported incidence of intraperitoneal (IP) 
adhesions varies from 67 to 93% after general intra-abdominal surgery and up to 97% after open 
gynaecologic surgery[1]–[3],[5]. Peritoneal adhesions affect quality of life by causing small bowel 
obstruction, female infertility, chronic abdominal pain and inadvertent organ injury after reoperative 
surgery [1]–[7].  
 Severe peritoneal adhesions are often observed after major surgery for abdominal malignancies. 
Cytoreductive surgery followed by IP chemotherapy is becoming the standard of care for patients with 
advanced cancers such as colorectal or ovarian tumours. Peritoneal carcinomatosis results from 
dissemination of primary intra-abdominal and gynecological cancers[8]–[14]. The effectiveness of IP 
chemotherapy depends on uniform drug distribution in the peritoneal cavity as well as on the 
concentration and exposure time of residual tumours to the instilled drugs. Adhesions occuring after 
cytoreductive surgery can compromise the effect of IP chemotherapy[15]–[17]. Therefore, a formulation 
that distributes evenly in the abdominal cavity, prevents peritoneal adhesions and simultaneously 
extends residence time and enhances local drug concentration is of high clinical interest. Biocompatible 
microspheres might be suitable candidates to meet these objectives. 
 Microparticles for IP drug delivery are promising since they can overcome some major 
challenges. They can distribute throughout the entire peritoneal cavity. Due to their size, they can remain 
in the peritoneal cavity and locally provide an extended release of a drug, such as a chemotherapeutic 
agent[16], [18]–[21]. The size range of the microspheres is crucial as size determines the residence time in 
the peritoneal cavity. Small particles can be cleared from the peritoneal cavity into the lymphatic 
capillaries through openings in the diaphragm (stomata), or they can be absorbed through the peritoneal 
membrane. The stoma openings are 3-12 µm in diameter and provide a direct access to the underlying 
submesothelial lymphatic system, allowing rapid removal of cells, fluid, bacteria and particles from the 
peritoneal cavity. Particles with a larger diameter are longer retained in the peritoneal cavity. Particle 
size will also affect drug release rate as smaller particles release the drug faster, due to their higher 
surface area-to-volume ratio. Furthermore, particle size will affect the spatial distribution in the 
abdominal cavity. Previous studies show that smaller microparticles are evenly distributed throughout 
the abdominal cavity whereas larger microparticles are mainly localized in the lower abdomen[16], [18], 
[20], [22]–[25]. 
 Microspheres for IP use should not cause an inflammatory reaction, nor should they have an 
intrinsic tendency to create peritoneal adhesions. Inflammation is dependent on the type of material and 
the particle size[15],[24]. The use of biocompatible and biodegradable polymers such as gelatine and 
collagen might overcome toxicity and biodegradability problems, which are related to the use of 
synthetic materials[26]. 
 Gelatin is an ideal candidate to formulate biocompatible microspheres. It has excellent film- and 
particle-forming capacities, as well as bioadhesive properties. Gelatin is not toxic or carcinogenic, and 
it is a readily available and inexpensive material. As a result, gelatin has been extensively used for 
medical, pharmaceutical and cosmetic applications[26]–[30]. However, its rapid dissolution in an aqueous 
environment under in vivo conditions requires the use of crosslinkers for long-term biomedical 
application of gelatin microspheres[26], [27], [29], [30]. 
 The selection of a chemical crosslinking agent is critical since residual crosslinking agent in the 
formulation can cause toxic side effects. Numerous chemical reagents have been used including 
glutaraldehyde, formaldehyde, diepoxide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide[28], [30]–
[32]. Genipin, a naturally occurring crosslinker, isolated from the fruits of the plant Gardenia jasminoides, 
is superior to other chemical crosslinking agents as it is 10 000 times less toxic than aldehyde and epoxy 
crosslinkers. Furthermore, genipin improves both thermal and structural stability of crosslinked gelatin 
since the degradation rate of genipin-crosslinked gelatin microspheres was significantly slower 
compared to aldehyde as crosslinker. Therefore, genipin is a promising crosslinking agent to formulate 
a long-acting biomedical implant[27], [32]–[35]. 
 This study presents the formulation and in vitro and in vivo characterization of genipin-
crosslinked gelatin microspheres. The aim of this study is to develop a formulation that evenly 
distributes in the peritoneal cavity. The potential efficacy of genipin-crosslinked gelatin microspheres 
to prevent postsurgical peritoneal adhesions is evaluated in a standardised mouse model[17].  
 
  
2. Materials and methods 
2.1  Formulation of gelatin microspheres 
 Gelatin microspheres were prepared by a modified emulsification solvent extraction method as 
reported by Adhirajan et al. (2007)[28]. 10 ml of a gelatin (Gelatin Type B, Rousselot, Ghent, Belgium) 
aqueous solution was added dropwise at 60°C to 100 ml of peanut oil (Fagron, Waregem, Belgium) pre-
heated to 60°C. Various concentrations (5, 10, 15, 20, 25 and 30 % (w/v)) and gelatin grades (75, 100, 
160, 200, 250 and 265 bloom) of gelatin were evaluated to obtain the appropriate size of the 
microspheres. The influence of the addition of surfactants to the size of microspheres was also 
investigated. A concentration of 0.1 wt% of surfactant (Tween®20 (Fagron), Tween®80 (Fagron,), 
Tween®85 (Sigma-Aldrich, Bornem, Belgium), Pluronic®L121 (BASF, Ludwigshafen, Germany), 
Pluronic®F127 (Sigma-Aldrich), Pluronic®F68 (Sigma-Aldrich), Cremophor®RH60 (BASF)) was 
added to the oil phase. A combination of two surfactants was evaluated where 0.1 wt% of surfactant A 
(Tween®80, Span®85 (Sigma-Aldrich)) was added to the aqueous phase and 0.1 wt% of surfactant B 
(Span®80, Tween®85 (Sigma-Aldrich)) to the oil phase. The two phases were emulsified for 15 minutes 
at 900 rpm using a magnetic stirrer. The emulsion was then rapidly cooled to 5°C in an ice bath and 
stirring continued for 20 minutes to allow the spontaneous gelation of the gelatin aqueous solution. The 
microspheres were dehydrated by the addition of 150 ml precooled acetone (Sigma-Aldrich) and stirring 
was continued for 30 minutes. The microspheres were collected by filtration using a cellulose filter 
(Whatman filter grade 4) and a vacuum pump. The microspheres were washed several times with 
acetone to remove residual oil from their surface. The washed microspheres were finally vacuum-dried 
at room temperature for at least 2 days.   
2.3  Crosslinking of gelatin microspheres 
 Gelatin microspheres were crosslinked using various genipin (Wako Chemicals, Neuss, 
Germany) concentrations and crosslinking times[33]. The prepared gelatin microspheres (500 mg) were 
dispersed in 10 ml 90% v/v ethanol (Sigma-Aldrich) solution containing different genipin 
concentrations (0.1, 0.5 and 1% w/v) and stirred at room temperature using a magnetic stirring for 
different time periods (5, 15, 24, 48, 72, 96 h). At the end of incubation, the genipin solution was 
aspirated and the crosslinked gelatin microspheres were rinsed with 15 ml aqueous ethanol solution 
(99.5% v/v) for 4 hours to remove residual genipin. Subsequently, the rinsed microspheres were filtered 
from the ethanol solution and vacuum-dried at room temperature for 24 h to remove ethanol. 
 
 
 
2.4  Characterization of microspheres 
 The morphology of gelatin microspheres in dispersed state was examined by optical microscopy 
(Leica DM2500 P).  
 Particle size and size distribution of the microspheres dispersed in water were measured in 
triplicate by laser diffraction analysis using a Mastersizer 2000 (Malvern Instruments, Malvern, 
Worcestershire, UK). The wet dispersion cell of the Mastersizer 2000 (Hydro 2000SM; Malvern 
Instruments, Malvern, Worcestershire, UK) was used. D(v, 0.1), D(v, 0.5) and D(v, 0.9) define the 
particle size of the volume distribution in microns where 10, 50 and 90%, respectively, of the particles 
are smaller than this diameter. 
 
2.5  Evaluation of the degree of crosslinking 
 A ninhydrin assay was performed to determine the degree of crosslinking by comparing the 
percentage of free amino groups in genipin-crosslinked gelatin microspheres and uncrosslinked gelatin 
microspheres[29], [35]. The ninhydrin reagent consisted of two solutions. Solution A contained 1.05 g citric 
acid (Fagron), 0.4 g NaOH (Sigma-Aldrich) and 0.04 g SnCl.H2O (Sigma-Aldrich) dissolved in 25.0 ml 
water. Solution B was made by mixing 1.0 g ninhydrin (Sigma-Aldrich) with 25.0 ml ethylene glycol 
monomethyl ether (Fisher Scientific, Erembodegem, Belgium). Solutions A and B were combined and 
stirred for 45 min in the dark at room temperature. Solutions of known concentrations of glycine (Sigma-
Aldrich) were prepared to generate a standard curve. Uncrosslinked and crosslinked microspheres were 
lyophilized prior to analysis. Samples of 3 mg lyophilized microspheres were weighed and rehydrated 
in 100 µL water. 1.0 ml ninhydrin solution was added to the samples and standard solutions, followed 
by incubation at 100°C for 20 min in the dark. Next, the samples were cooled to room temperature and 
5.0 ml 50% isopropanol (Fisher Scientific) was added to each sample. The optical absorbance of the 
solutions at 570 nm was recorded with a spectrophotometer (UV-1650PC, Shimadzu Benelux, Antwerp, 
Belgium). The amount of free amino groups in the sample, after heating with ninhydrin, is proportional 
to the optical absorbance of the solution. The concentration of free NH2 groups in the sample is 
determined from a standard curve of glycine concentration versus absorbance. The degree of 
crosslinking of the sample is calculated following the equation: 
degree of crosslinking= 	 (NHN reactive amine)non-crosslinked -	(NHN reactive amine)crosslinked
(NHN reactive amine)non-crosslinked	
 
where 'non-crosslinked' is the mole fraction of free NH2 in non-crosslinked samples and 'crosslinked' is 
the mole fraction of free NH2 remaining in crosslinked samples. Each measurement was performed in 
triplicate. 
 
2.6 Evaluation of in vitro degradation 
  An in vitro enzymatic degradation test was carried out using collagenase[27], [28], [32]. Fifty mg of 
microspheres was suspended in 5 ml reaction buffer containing 50 mM Tris (Sigma-Aldrich), 2 mM 
CaCl2 (Sigma-Aldrich), 20 U/ml collagenase type I (Sigma-Aldrich) and incubated at 37°C for 48 h. 
Samples of 200 µL were taken after 5, 24 and 48 h. 200 µl of quenching buffer (12% w/v PEG 6000 
(Sigma-Adrich) and 25 mM EDTA (Fagron) in water) was added to prevent further degradation. 
Ninhydrin assay was performed to quantify the percentage of degradation[36]. 2 ml of ninhydrin solution, 
prepared as described in section 2.5, was added to the samples. The reaction was carried out at 100°C 
for 10 minutes in the dark. Samples were cooled to room temperature and 2 ml 50% v/v isopropanol 
(Fisher Scientific) was added. Optical absorbance of the solutions was measured at 570 nm using a 
spectrophotometer (UV-1650PC, Shimadzu Benelux, Antwerp, Belgium). The absorbance at 570 nm 
was proportional to the amount of degradation. An increase in degradation resulted in more free amino 
acids and therefore higher absorbance. Percentage of degradation was compared to degradation of non-
crosslinked gelatin microspheres.  
 A hydrolytic degradation study was performed by dispersing uncrosslinked and genipin-
crosslinked gelatin microspheres (GP-MS) in 5 ml phosphate buffered saline (PBS) and incubated at 
37°C for the duration of the study. The morphology of the microspheres was daily observed using optical 
microscopy (Leica DM2500 P)[37]. 
2.7  In vitro cell viability 
 The human ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture 
Collection) was cultured at 37°C in a 5% CO2-containing humidified atmosphere in McCoys medium 
(Invitrogen, Merelbeke, Belgium). Medium was supplemented with 10% fetal bovine serum, penicillin, 
streptomycin (Invitrogen) and fungizone (Bristol Myers Squibb, Braine-l'Alleud, Belgium).  
 To test the cytotoxicity of the crosslinker a broad range of genipin concentrations was evaluated 
(0.0001, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5 % w/v), and an MTT assay was performed after 24, 48, 
96 h and 1 week of incubation. To evaluate the cytotoxicity, 30 x 103, 25 x 103, 20 x 103 and 10 x 103 
cells/well were seeded in 96-well plates (Starstedt, Newton NC, USA). After 48 h, 20 µl medium was 
replaced by 20 µl genipin solution. After 24 h, 48 h, 96 h or 1 week incubation at 37°C under 5% CO2-
atmosphere, medium was entirely removed, cells were washed three times with PBS and 200 µL medium 
was added to each well. The cytotoxicity of GP-MS was tested at 0.1, 1.0 , 2.5, 5.0, 10, 25 and 50 mg/ml. 
30 x 103, 25 x 103, 20 x 103, 10 x 103 and 5 x 103 cells/well were seeded in 96-well plates for incubation 
with the formulation during 24 h, 48 h, 96 h, 1 week or 2 weeks, respectively. After 48 h, 20 µl medium 
was replaced by 20 µl formulation. After the required incubation period at 37°C under 5% CO2-
atmosphere, the medium was entirely removed, cells were washed three times with PBS and 200 µL 
medium was added to each well. Six wells per concentration were used and all experiments were 
performed in triplicate. Cell viability was determined via the MTT assay and compared with non-treated 
cells. 
 The MTT assay was performed by replacing 100 µl medium by 100 µl MTT-reagent (3-(4,5 
dimethylthiazol-2-yl)-2,5-difenyl-tetrazolium bromide) (Sigma-Aldrich) at a concentration of 1 mg/ml 
in PBS-D+ (Thermo Fischer Scientific). The plates were incubated in the dark for 2 h at 37°C and 5% 
CO2-atmosphere. Afterwards, all medium was removed and 200 µL DMSO (Acros Organics, Geel, 
Belgium) was added to dissolve formazan crystals. Optical density was measured at 570 nm, 
normalizing with a reference wavelength of 650 nm using an ELISA-plate reader (Paradigm Detection 
Platform, Beckman Coulter, Suarleé Belgium).   
 Genipin leaching, the amount of genipin released from the microspheres, was evaluated. 50 mg 
of GP-MS  (0.5% wt genipin; 5, 15, 24, 48, 72 and 96 h of crosslinking) were immersed in 5 ml PBS at 
37°C. Genipin leaching over time was analysed by measuring optical absorbance of supernatans at 240 
nm. 
2.8  Animal study 
 All animal experiments were approved by the Ethical Committee of the Faculty of Medicine, 
Ghent University (ECD 14/11). Female Balb/c mice (Envigo, Horst, The Netherlands) were kept in 
standard housing conditions with water and food ad libitum and a 12 hours light/dark cycle. 
2.8.1 In vivo biocompatibility, degradability and toxicity study  
 15 Balb/c mice, aged 6 weeks, received an IP injection of the formulation into the left lower 
quadrant. GP-MS were sterilised in ethanol solution prior to administration. 50 mg sterilised gelatin 
microspheres, crosslinked using 0.5% w/v genipin for 48 h, were suspended in 2 ml sterile physiological 
saline (Baxter, Lessines, Belgium) and injected. All animals were observed after administration of the 
formulation, including general condition (activity, energy, hair, faeces, behaviour pattern and other 
clinical signs), body weight and mortality. After 2, 7, 14, 21 and 28 days three mice per time point were 
sacrificed by cervical dislocation under anaesthesia with sevoflurane (Sevorane®, Abbott, Waver, 
Belgium). A vertical incision along the midline through the abdominal wall muscle and peritoneum was 
made and the abdominal cavity was exposed. Distribution, compatibility and degradability of GP-MS 
were examined. The abdominal cavity was photographed. Specimens of cecum, colon, greater omentum 
and parietal peritoneum were assigned for histopathological examination to evaluate local tolerance. 
Specimens of spleen, pancreas, liver and kidneys were taken to evaluate general toxicity. Tissues were 
fixed immediately by immersion in 4% paraformaldehyde in PBS for 72 hours and embedded in paraffin. 
The tissues were then sectioned, stained with hematoxylin and eosin (H&E). All slides were examined 
for tissue inflammatory reaction by a pathologist in a blinded manner. 
2.8.2 Effectiveness of gelatin microspheres in prevention of postoperative peritoneal 
 adhesions 
2.8.2.1.  Influence of GP-MS to the mechanism of adhesion formation over time 
 15 Balb/c mice, aged 6 weeks, were sedated by inhalation anaesthesia with sevoflurane, 
induction 8% and maintenance 3%. Prior to anaesthesia, mice received a subcutaneous injection of 
buprenorphine 0.05 mg/kg (Temgesic®, Schering-Plough, Heist-op-den-Berg, Belgium). Body 
temperature was controlled using a heating plate. 
 Peritoneal adhesions were induced by the abdominal wall and cecum abrasion peritoneal 
adhesion model as previously reported[17], [38], [39]. An anterior midline incision was made through the 
abdominal wall and peritoneum. The cecum was identified and abraded until visible damage by 
scrubbing with sterile dry surgical gauze. The damaged cecum was returned to the abdominal cavity and 
a 1x1 cm apposing parietal peritoneal wall defect was created using a sterile dry gauze. No attempt of 
hemostasis or IP irrigation was made. The abraded cecum was placed in apposition to the peritoneal 
wall defect. Then, the incision was closed in two layers with a PDS II 6/0 suture (Ethicon®,  Johnson & 
Johnson, Sint Stevens Woluwe, Belgium).  
 After complete closure, 12 Balb/c mice (GP-MS-treated mice) were intraperitoneally injected 
in the left lower quadrant with the formulation. Fifty mg of  
GP-MS, crosslinked using 0.5% w/v genipin for 24 h and sterilised by immersion in ethanol solution, 
were dispersed in 2 ml of sterile physiological saline (Baxter) and injected. Three Balb/c mice (control 
mice) received an IP injection of 2 ml of physiological saline (Baxter) in the left lower quadrant. Mice 
were checked daily for changes in behaviour (feeding, grooming, etc.) and body weight was monitored.  
 The anti-adhesion efficacy of GP-MS was evaluated 2, 7 and 14 days post-operative, 3 GP-MS-
treated mice and 1 control mouse per time point. Mice were sacrificed by cervical dislocation under 
anaesthesia with sevoflurane. Abdominal cavity was exposed and tissues were investigated on typical 
inflammatory signs. Adhesions were qualified and quantified using standard scoring systems. The 
qualitative adhesion scoring (Table 1) was based on extent, type and tenacity of adhesions, as described 
by Binda et al. (2007)[40], [41] with some modifications. 
 The extent of adhesion was assessed by the area of the peritoneal cavity that was covered by 
adhesions. Therefore, the abdominal cavity was hypothetically subdivided into 8 sections, each 
consisting 12.5% of abdominal area, as illustrated in Figure 1[41], [42]. 
 Adhesions were assessed according to the quantitative scoring system reported in Egea et al. 
(1995) with some modifications[42] as displayed in Table 2.  
  Specimens for histopathological examination were taken from the cecum, abdominal wall and, 
if applicable, adhesion tissue. The tissues were fixed immediately by immersion in 4% 
paraformaldehyde in PBS for 72 h and embedded in paraffin. The tissues were then serially sectioned, 
stained with H&E and analyzed using light microscopy by a pathologist in a blinded manner. 
2.8.2.2 . Proof of concept: effectiveness of GP-MS in the prevention of postsurgical  
  peritoneal adhesions in a standardized mouse model 
 A large scale study was performed to compare the effectiveness of GP-MS to the commercially 
available Hyalobarrier® gel (n=11) (Anika Therapeutics, Abano Terme, Italy) in the prevention of 
postsurgical peritoneal adhesion formation in a standardized mouse model. Mice of the control group 
(n=11) were only treated with saline. Mice were at random assigned to control, GP-MS or Hyalobarrier® 
group. 
 Peritoneal adhesions were induced by the abdominal wall and cecum abrasion peritoneal 
adhesion model as described above. After complete closure of the anterior midline incision, 2 ml of 
0.9% NaCl (Baxter) or 50 mg GP-MP dispersed in 2 ml of 0.9% NaCl were IP injected in the left lower 
quadrant of 11 Balb/c mice in the control and GP-MP arm, respectively. Gelatin microspheres, 
crosslinked for 24 h in 0.5% m/v genipin, sterilized by immersion in 96% v/v ethanol (Sigma-Aldrich) 
solution for 4 hours prior to IP administration. Hyalobarrier® gel (4% ACP, Anika Therapeutics) (n=11) 
was applied in a thin layer to the lateral and ventral surface of the damaged cecum and the 1x1 cm 
parietal peritoneal defect before closure of the abdomen according to the manufacturer’s instructions. 
All proceedings were performed under clean conditions by one surgeon in a blinded way. Mice were 
monitored for recovery from anesthesia and their general conditions and body weight were followed 
daily. 
 At day 14 a second ventral laparotomy was performed, the abdominal cavity was exposed and 
tissues were investigated on typical inflammatory signs. In addition, adhesions were qualified and 
quantified in a blinded manner using three scoring systems. Qualitative adhesion scoring was based on 
extent, type and tenacity of adhesions, as described by Binda et al. (2007) with some modifications[40], 
[41] as displayed in Table 1. Adhesions were assessed according to the quantitative scoring system 
reported in Egea et al. (1995) with some modifications[41], [42] as displayed in Table 2. Additionally, 
adhesions were graded (Table 3) according to the Zühlke grading classification[41], [43].  
  Specimens for histopathological examination were taken from the cecum, abdominal wall and, 
if applicable, adhesion tissue. The tissues were fixed immediately by immersion in 4% 
paraformaldehyde in PBS for 72 h and embedded in paraffin. The tissues were then serially sectioned, 
stained with H&E and analyzed using light microscopy by a pathologist in a blinded manner.  
 Blood samples were obtained from the tail vein of mice prior to induction of adhesions, at day 
1 and 7 postoperative. At day 14 blood was obtained by intracardiac puncture using a 27 G needle and 
mice were sacrificed by cervical dislocation under anesthesia sevoflurane. The blood samples were 
centrifuged at 2500 rpm during 10 minutes. Additionally, peritoneal lavages were performed at day 0, 
1, 7 and 14. Five ml of cooled PBS was intraperitoneally injected, abdomen was gently massaged and 
peritoneal fluid was collected. Quantification of cytokines interleukin (IL) 1ß, IL-6 and TNF- in 
plasma and peritoneal fluid was performed using ELISA kits (Qiagen, Antwerp, Belgium).  
 Statistical analysis were performed using the nonparametric Wilcoxon-Mann Whitney test in 
GraphPad Prism™ version 5.2 to compare the total adhesion score, grade and extent of adhesion 
between each pair of treatment groups. The incidence of adhesions was compared using the Fisher’s 
Exact test. A P-value < 0.05 on a two-tailed test was considered to be statistically significant. 
 
 
 
 
  
3. Results and discussion 
 
3.1  Formulation of gelatin microspheres 
 
 The size of gelatin microspheres can be controlled by adjusting the concentration of gelatin in 
the aqueous phase. A higher gelatin concentration increases the size of the aqueous droplets in emulsion 
and thus the size of the final gelatin microspheres. Nevertheless, a minimum viscosity is necessary for 
a good emulsification process as no microspheres or microspheres with a poor morphology were formed 
when an aqueous gelatin solution of 5 and 10 w/v % was used. A gelatin with a high gel strength (i.e. 
bloom value of 265) was selected as this gelatin grade yielded microspheres with a better spherical 
morphology in comparison to gelatin grades with bloom values of 160, 200 and 250. Microspheres were 
not formed when a gelatin grade of 75 and 100 bloom was used. Aggregation tendency of the 
microspheres depended on the bloom value of gelatin: less aggregation was observed at higher bloom 
value. Addition of surfactants also controls the size of microspheres by reducing the size and the 
aggregation tendency of the gelatin droplets during the emulsification process[26]. Figure 2 displays laser 
diffraction results, illustrating how the final microspheres size can be managed by the concentration of 
the gelatin solution and the addition of a surfactant.   
 
 The influence of different types of surfactants, i.e. sorbitan esters (Span®) and their ethoxylates 
(Tween®), poloxamers (Pluronic®) and polyethoxylated castor oil (Cremophor® RH), on the size of 
microspheres was investigated. The influence of the surfactants on the size of the microspheres is 
displayed in Table 4, presenting the volume mean diameter, D[4,3]. The addition of 0.1 wt% 
Cremophor® RH 60 (polyoxyl 60 hydrogenated castor oil) to the oil phase resulted in the smallest 
microspheres with a narrow size distribution, low aggregation tendency and good spheroid morphology.  
 Microspheres with a size of about 50 µm were selected for further experiments based on their 
intended use for IP administration since smaller sized microspheres are more easily to inject 
intraperitoneally. To obtain microspheres of  50 µm, 15 w/v% gelatin (265 bloom) solution was added 
dropwise to 100 ml of peanut oil with 0.1 wt% Cremophor®RH60, emulsified and extracted as described 
above. The obtained microspheres had a volume mean diameter, D[4,3], of 58 ± 10 µm and a span of 
1.22 in the dispersed state. A spherical morphology of the microspheres without tendency towards 
aggregation was observed.  
3.2  Crosslinking of gelatin microspheres 
 Gelatin microspheres were crosslinked using genipin in various concentrations and crosslinking 
times. Blue coloration increased with higher genipin concentration and a longer incubation time: 
ninhydrin assay confirmed that a higher degree of crosslinking is obtained when increasing genipin 
concentration and crosslinking time (Figure 3).  
 Genipin can react with the free amino groups of lysine, hydroxylysine and arginine residues in 
proteins to form intra- and intermolecular crosslinks. The reaction between a genipin and an amino acid 
in gelatin is initiated by a nucleophilic attack of the amino group on the third carbon of genipin. The 
genipin ring is opened and an aldehyde group is formed. The resulting aldehyde group is attacked by 
the attached secondary amine group. Further radical reaction leads to dimerization. Hence, genipin may 
link peptide chains by introducing a dimeric genipin spacer with a cyclic structure. Consequently, 
genipin can form intramolecular crosslinks within a gelatin molecule and short-range intermolecular 
crosslinks between two adjacent gelatin molecules[27], [29], [44]. Intermediates formed during the 
crosslinking reaction are linked to the blue coloration. Some suggest that genipocyanin is a major 
component, a result of a 1:1 reaction between genipin and amino acid. Spontaneous reaction of genipin 
as azaphilone with an amino group forms a nitrogen-iridoid which undergoes dehydration to form an 
aromatic monomer[45]. Others speculate that genipin molecules may be polymerized before crosslinking 
with amino groups[31].    
 Crosslinking gelatin microspheres did not induce changes in morphology or size. Photographs 
of GP-MS in the dispersed state are displayed in Figure 4. Microspheres crosslinked during 5 h and 24 
h had a mean volume diameter of 57.11 ± 5.03 µm (n=3) and 55.53 ± 5.08 µm (n=3), respectively. 
3.3  In vitro degradation  
 The degradation mechanism of the microspheres is probably a combination of hydrolysis and 
proteolysis. Therefore, two types of degradation assays were performed. Proteolysis can be accelerated 
in case of metastasis as it has been noticed that tumour cell invasion and metastasis are related to a 
higher expression of degrading enzymes, such as heparanase, serine protease, thiol protease and metal-
dependent enzymes. A shift in proteolytic balance of proteases facilitates the matrix modulation in the 
metastatic cascade.  Tumour cells can directly secrete degrading enzymes or induce proteinase activity 
in neighbouring cells. Matrix metalloproteinases (MMP) play an important role in extracellular matrix 
degradation. MMP collagenase I was chosen as model enzyme as it is most widely expressed. 
Collagenase I is secreted by both normal cells, eg. stromal fibroblasts, macrophages, endothelial and 
epithelial cells, as well as by tumour cells[46]–[49]. The in vitro proteolytic study allowed a rapid evaluation 
of the biodegradability. Enzymatic degradation properties of microspheres are displayed in Figure 5. All 
microspheres were degraded within 48 hours. An increase in degree of crosslinking and genipin 
concentration resulted in a longer resistance to enzymatic degradation. 
 The resistance of GP-MS to hydrolysis was evaluated (Table 5). Microspheres longer remained 
intact when a higher genipin concentration and longer duration of crosslinking was used. Microspheres 
crosslinked with 0.1 w/v % genipin were all degraded within 8 days, whilst using concentrations of 0.5 
and 1.0 w/v % genipin increased the resistance of microspheres to degradation. Microspheres 
crosslinked for 96 h with 1.0 w/v % genipin remained intact for about 60 days.  
  The degree of crosslinking allowed to tailor the degradation rate of microspheres and thus their 
residence time. 
 
3.4  In vitro cell viability 
 Previous reports describe low cytotoxicity of genipin as crosslinking agent in comparison to 
aldehyde crosslinkers[27], [32]–[35]. This study evaluated the influence of genipin on cell viability of SKOV-
3 cells. Both concentration- and time-dependent influence of the crosslinking process on cell viability 
are evaluated since the gelatin microspheres are intended to be retained for a prolonged period in the 
peritoneal cavity (Figure 6A). 
 MTT assays clearly indicated that genipin influenced cell viability at high concentrations. 
Concentrations of 0.5 w/v % and higher caused a steep decrease of cell viability after one day of 
incubation. Cell viability decreased further in time to a minimum of 20%. Acute cytotoxicity was noticed 
with a minimum cell viability of 25% after 48 h of exposure to 0.5 w/v % genipin. Surprisingly, cells 
seemed to recover in time which could reflect the loss of cell-cell contacts and mitochondrial 
reactivation[50], [51]. Low genipin concentrations (0.0001 to 0.01 w/v %) hardly had an effect on cell 
viability, while concentrations of 0.05 and 0.1 w/v % affected cell viability with a gradual decrease in 
function of time. Hence, only the lowest genipin concentrations (0.0001 to 0.005 w/v %) can be 
considered as non-cytotoxic. Since the cytotoxicity of genipin is determined by the free concentration 
of the crosslinker exposed to cells, leaching of genipin from microspheres was evaluated. The amount 
of genipin released from the microspheres was very low and within the non-cytotoxic concentration 
range. Measured genipin concentrations ranged from 0.00007 w/v % (70% degree of crosslinking) to 
0.001 w/v % (40% degree of crosslinking) and 0.004 w/v % (<40% degree of crosslinking). Based on 
the aforementioned cytotoxicity data, it is hypothesised that the free genipin released from the 
microspheres will not affect cell viability. The low amount of genipin released from the crosslinked 
microspheres is linked to the stable nature of the inter- and intramolecular crosslink [27], [31], [44].   
 This hypothesis was confirmed by performing a new set of MTT assays where SKOV-3 cells 
were exposed to several concentrations of GP-MS with a degree of crosslinking of 60%. Figure 6B 
indicates that cell viability was not affected by the presence of GP-MS. Neither exposure time nor 
concentration of GP-MS had an influence on cell viability. 
3.5 Animal study 
3.5.1 In vivo distribution pattern, biocompatibility and degradability 
 Animals were followed during the entire period of the study and all of them tolerated the 
formulation well. Body weight gain was not different from the standard body weight increase and 
general activity was normal. The formulation consisted of GP-MS with a 60% degree of crosslinking 
using 0.5 w/v % genipin as crosslinking concentration. A high degree of crosslinking was chosen to 
ensure a long retention time in the peritoneal cavity in order to obtain information on the short and 
longer term inflammatory and toxicity responses. 
 The distribution of GP-MS in the abdominal cavity was visually evaluated (Figure 7) based on 
the blue colour of the particles. The microspheres displayed a distribution pattern similar to the flow of 
peritoneal fluid. The gelatin microspheres distribute throughout the whole abdominal cavity, from 
injection site to colon, cecum, omentum, diaphragm and liver, and accumulation of the formulation at 
the typical sites of peritoneal carcinomatosis was seen. The peritoneal carcinomatosis pattern has been 
described and tumour growth was predominantly found in the following locations: in the small pelvis, 
at the end of the ileal mesentery, at the sigmoid colon, and at the right paracolic gutter (cecum, ascending 
colon)[52], [53]. Thus, the distribution pattern of the microspheres is an attractive characteristic in view of 
its intended use for drug delivery in the treatment of peritoneal carcinomatosis. Upon examination of 
the abdominal cavity and organs there were no visible signs of inflammation or intolerance caused by 
the presence of the formulation. Previous studies showed that biodegradable poly-(lactic-co-glycolic) 
acid microspheres with a size range of 5 to 250 µm caused peritoneal adhesions and chronic 
inflammation after IP injection whilst nanoparticles caused fewer adhesions but were rapidly cleared 
from peritoneal cavity [24].  All tissues had a normal, healthy appearance and there were no adhesions 
observed after IP injection of GP-MS. Histopathological examination of the tissues confirmed that there 
were no signs of inflammation nor intolerance (Suppl. Figure 1a and 1b). No abnormalities were 
observed in colon, cecum, greater omentum, parietal peritoneum and spleen, liver, pancreas or kidneys 
compared with the control group. To our knowledge, microspheres for IP administration that do not 
cause inflammation or intolerance have not yet been described. Nanoparticles are mainly used to achieve 
these requirements[24], [54], [55]. Since they suffer from rapid clearance, incorporation of nanoparticles into 
hydrogels has been reported[54]. 
 The formulation remained intact in the peritoneal cavity at day 2, 7, 14 and 21. A gradual 
decrease of the amount of microspheres over time was noticed, indicating the biodegradation of the 
formulation. At day 28, only a small amount of microspheres was still present in the abdominal cavity.   
3.5.2 Effectiveness in prevention of postoperative peritoneal adhesions 
 Adhesions were induced by the abdominal wall and cecum abrasion peritoneal adhesion model 
as has described extensively[6], [17], [38], [56], [57]. The model is highly reproducible and adhesion formation 
can be easily scored. However, this model might not entirely relate to the clinical appearance of 
peritoneal adhesions after an abdominal operation, where adhesions are found spread throughout the 
peritoneal cavity and in between intestines. Nonetheless, the model provides a good indication of the 
effectiveness of the formulation and allows follow-up of the healing of peritoneum and cecum. GP-MS 
crosslinked using 0.5 w/v% genipin during 24 h were chosen as formulation to prevent peritoneal 
adhesions since a degree of crosslinking of 40% ensures complete degradation of the GP-MS within 14 
days. Microspheres of 50 µm were chosen for in vivo studies since pilot studies using particles of 50, 
100, 200 and 300 µm showed that the larger the particles, the more difficult to inject and particles were 
more evenly distributed in the peritoneal cavity using a smaller particle size.  
3.5.2.1. Influence of GP-MS to the mechanism of adhesion formation over time 
 Scoring of adhesions was conducted 2,7 and 14 days after the induction of adhesions (Table 6). 
All control mice (Figure 8) developed peritoneal adhesions. Cecum was attached to peritoneal wall 
(parietal adhesions) and dense adhesions were seen between colon-cecum and small intestines-cecum 
(visceral adhesions). Sharp dissection was required to separate the adhesions. At day 14, adhesions were 
vascularised. It is accepted that peritoneal remesothelization is completed by day 8 after peritoneal 
injury, thus formed adhesions will remain and vascularisation is initiated. Whilst peritoneal adhesions 
were formed in all control mice, none of the mice treated with GP-MS developed adhesions (Figure 9). 
At day 2, the formulation was evenly distributed throughout the peritoneal cavity. The microspheres 
adhered to the affected peritoneum and cecum, forming a barrier to prevent traumatized peritoneal 
surface apposition during the healing process. No adhesions were found in GP-MS-treated mice 7 days 
after induction of peritoneal adhesions. GP-MS were completely degraded 14 days after induction of the 
adhesions, confirming the biodegradability of the formulation. None of the GP-MS-treated mice 
developed adhesions, peritoneal and cecal injuries appeared healthy and recovered.  
 Abdominal wall and viscera are covered by a peritoneal layer consisting of mesothelial cells and 
an underlying extracellular matrix. Peritoneal wounds remesothelialize within 5-6 days for the parietal 
peritoneum and within 5-8 days for both visceral mesothelium covering the terminal ileum and the 
mesothelial layer of the parietal peritoneum. The mechanism of adhesion formation can be considered 
as a variation of the physiological healing process. Injuries to the peritoneum cause a local release of 
cytokines, IL-1, IL-6 and tumour necrosis factor- (TNF-), as a response to trauma. Cytokines attract 
and activate macrophages to secrete variable substances, including cyclooxygenase and lipoxygenase 
metabolites, plasminogen activator, plasminogen activator inhibitor (PAI), collagenase, elastase, IL-1 
and 6, TNF-, etc. Postsurgical macrophages recruit new mesothelial cells to lead to peritoneal 
remesothelialization in response to macrophage-secreted mediators. Formation of the fibrin matrix is of 
major importance in the adhesion formation cascade. The fibrin clot is formed in several stages from 
fibrinogen to fibrin monomer, then to soluble fibrin polymer and finally insoluble polymer by 
coagulation factors. Normally most of the fibrin depositions will disperse by fibrinolysis. The fibrinous 
mass that remains, results in the organization and formation of adhesions [1], [2].  
 The balance between deposition and degradation of fibrin will determine normal peritoneal 
healing or adhesion formation. Fibrinolytic activity usually begins three days after peritoneal injury and 
increases to a maximum by day 8. Therefore, peritoneal adhesions will remain when 
remesothelialization is completed by day 8. Normal peritoneum has a high fibrolytic activity to prevent 
adhesion formation. But at sites of surgical or inflammatory injury, levels of PAI are increased, which 
inhibit fibrinolytic activity. Additionally, deficient blood supply and reduced tissue oxygenation, 
typically for surgical injury, decrease fibrinolysis resulting in adhesion development [1], [2]. Three time 
points (day 2, 7 and 14) were chosen to evaluate the complete cascade of peritoneal adhesion formation. 
The microspheres were able to form a barrier between the injured peritoneal surfaces of cecum and 
parietal peritoneum, thereby hindering the formation of fibrin strands during the remesotheliazation 
phase. At day 14, when peritoneal healing is completed, adhesions will remain[1], [2]. GP-MS-treated 
mice did not develop peritoneal adhesions and the peritoneal layer covering abdominal wall and viscera 
had a normal appearance by day 14. In contrast, control mice developed peritoneal adhesions which 
were vascularised by day 14 since there was no IP barrier present.  
 Histopathological analysis of cecum, peritoneum and adhesion tissue allowed to further evaluate 
the differences in formation of peritoneal adhesions in time between control and GP-MS-treated mice. 
Tissue samples of control mice clearly showed inflammation. Two days after induction of peritoneal 
adhesions (Suppl. Figure 2a), a limited to mild active inflammation of the cecal serosa was seen, while 
the cecal mucosa displayed a normal architecture. Peritoneal tissue also displayed mildly active 
inflammation. Adhesion tissue consisted of adipose tissue, infiltrated by neutrophils, and lymphoid 
follicles were occasionally observed. In comparison, in all cecal samples of GP-MS-treated mice, the 
serosa displayed limited inflammation as only few neutrophils and lymphocytes were present. Cecal 
mucosa did not display any abnormalities. Some neutrophils and lymphocytes were also noticed in 
peritoneal tissue, without infiltration into muscle tissue, indicating a mildly active inflammatory 
response.  
 Seven days after induction of peritoneal adhesions (Suppl. Figure 2b) extended inflammation of 
cecal serosa was observed in control mice. Both neutrophils and lymphocytes were noticed at the entire 
surface of the serosa. Peritonitis is clearly observed in control mice with extension of the inflammation 
into muscle tissue of abdominal wall. Adhesion tissue consisted of adipose tissue with inflammatory 
cells and lymphoid aggregates. Cecal serosa and mucosa of GP-MS-treated mice displayed no 
irregularities at day 7, whereas a small amount of inflammatory cells was observed in peritoneal tissue. 
No infiltration into muscle tissue of abdominal wall was seen.       
 Fourteen days after induction of peritoneal adhesions (Suppl. Figure 2c), adipose tissue 
associated with cecum of control mice, i.e. adhesion tissue, showed a severe inflammatory infiltrate. 
Cecal mucosa displayed normal architecture whereas serositis was observed. Peritoneal tissue still 
showed active inflammation after fourteen days. Inflammatory cells were observed in adipose, 
connective and muscle tissue. Chronic inflammation was seen upon observation of adhesion tissue. 
Cecal mucosa and serosa of GP-MS-treated mice had a normal appearance without signs of 
inflammation. Peritoneal tissue of most mice was healed after abrasion, although in some cases, a few 
inflammatory cells were observed. None of the tissues showed penetration of inflammatory cells into 
abdominal wall muscle tissue.  Thus, histopathological examination showed that inflammatory reaction 
of cecum and peritoneum decreased over time. Cecum and peritoneum recovered and displayed normal 
histological appearance. Quantification of inflammatory markers, cytokines in plasma and peritoneal 
fluid, is performed in the proof-of-concept study detailed below. This permits confirmation of the 
hypothesis that GP-MS are able to reduce formation of peritoneal adhesions and allow healing of 
peritoneal wounds.  
3.5.2.2. Proof of concept: effectiveness of GP-MS in the prevention of postsurgical peritoneal 
 adhesions in a standardized mouse model 
 All animals had a healthy appearance and their general activity was normal. Furthermore, they 
gained body weight after the surgical procedure. Adhesions were seen in all control mice and animals 
of the comparison group (Hyalobarrier®). In the intervention group (GP-MS treated mice) 36% of the 
mice developed at least one adhesion, which represented a statistic significant reduction of 64% in 
incidence compared to the control group (P=0.0039; Fisher’s Exact). The high incidence (100%) of 
adhesions noticed in the control group indicates that the standardized adhesion model is adequate to 
evaluate the effectiveness of agents in the prevention of postsurgical peritoneal adhesions. 
 The results of the quantitative scoring of the peritoneal adhesions are displayed in Table 7. 
Visceral adhesions were seen in all animals of the control (Figure 10A) and Hyalobarrier® group (Figure 
10D), compared to 18% of GP-MS treated mice (Figure 10F). The mice predominantly developed 
intestine-intestine adhesions. Parietal adhesions were seen in 64% and 45% of mice in the control 
(Figure 10B) and Hyalobarrier® group (Figure 10C), respectively. Parietal adhesions were observed in 
18% of GP-MS treated animals. At day 14, adhesions were vascularized in 91% of mice in the control 
group compared to 9% of animals in the GP-MS group. Vascularized adhesions were observed in 82% 
of Hyalobarrier®-treated mice. It should be noted that when intestines are immediately attached to the 
peritoneal wall, observation of vascularization is not possible, hence there are no fibrous adhesion 
strands present.  
 Results of the qualitative assessment of peritoneal adhesions are displayed in Table 8. The total 
adhesion score of the control group was 7.90 ± 1.70 compared to 1.18 ± 1.78 in the GP-MS group. The 
difference in total score between both groups was statistically significant (P < 0.0001; Wilcoxon-Mann 
Whitney). In addition, the GP-MS group (1.18 ± 1.78) and Hyalobarrier® group (8.36 ± 1.91) differed 
significantly in total adhesion score (P < 0.0001; Wilcoxon-Mann Whitney), whereas no statistically 
significance was reported between Hyalobarrier® and control group (P=0.42; Wilcoxon-Mann 
Whitney).  
 Dense adhesions were observed in 82% and 91% of mice in the Hyalobarrier® and control group, 
respectively, whereas only filmy adhesions were seen in the GP-MS group. Furthermore, adhesions of 
GP-MS treated mice were very localized (extent of 0.45 ± 0.69) and felt easily apart. The 4 GP-MS-
treated mice where adhesions were observed had only 1 or 2 filmy adhesions which did not lead to 
clinical relevant complication[58]. Extended adhesions where ± 70% of peritoneal cavity was involved, 
were observed in Hyalobarrier® (extent of 3.00 ± 1.10) and control group (extent of 2.64 ± 0.47). The 
adhesions mainly required sharp dissection to separate and was not possible without damaging of viscera 
of intestines or peritoneum.  
 An overview of the evaluation of the adhesion grading according to the Zühkle classification is 
displayed in Table 9. All control mice developed grade 3 (55%) or 4 (27%) peritoneal adhesions except 
for two (18%) mice, who had grade 2 adhesions. Hyalobarrier®-treated mice developed grade 3 (27%) 
or 4 (64%) peritoneal adhesions, except for one mouse (9%) with grade 2 adhesions. No adhesions 
(grade 0) were observed in 64% of GP-MS-treated mice and 36% developed grade 1 adhesions. 
Consequently, a significant lower grade of adhesion was seen in the GP-MS-treated mice (0.36 ± 0.50) 
compared to the control group (3.09 ± 0.70) and comparison group (3.55 ± 0.69), respectively (P < 
0.0001; Wilcoxon-Mann Whitney). Control and Hyalobarrier® group did not differ statistically 
significant in grade of adhesion (P=0.1432; Wilcoxon-Mann Whitney).  
 It can be concluded that GP-MS are able to prevent formation of postsurgical adhesions since 
each scoring system, quantitative and qualitative scoring and grading of adhesions, demonstrates a 
statistic significant reduction in extent, type, tenacity or adhesion grade when compared to the control 
or Hyalobarrier® groups. Remarkably, Hyalobarrier® did not significantly reduce peritoneal adhesions. 
Hyalobarrier® gel was selected since it has a similar characteristics as GP-MS (mechanism of action, 
biodegradable, gel). Hyalobarrier® gel is a sterile, transparent and highly viscous gel, registered in 
Europe for open surgical procedures. Beside, Hyalobarrier® gel Endo is available in Europe, which is 
indicated for laparoscopic and hysteroscopic surgery. Hyalobarrier® gel is composed of 4% auto-
crosslinked polysaccharide (ACP) in contrast to Hyalobarrier® Endo, a 3% ACP gel. The ACP polymers 
are obtained through an auto-crosslinking process that results in intra- and intermolecular condensation 
of hyaluronic acid[59]–[61]. Although Seprafilm®, Interceed® and Adept® are most commonly used in 
clinical practice[62], the effectiveness of GP-MP was compared to Hyalobarrier® gel. In contrast to 
Hyalobarrier® gel, Seprafilm® and Interceed® are absorbable solid devices, which are applied as a film 
on the injured surfaces. Adept® was not selected since it is a liquid barrier instead of a solid device and 
thereby attempts to separate injured surfaces by hydroflotation[1]. Additionally, Adept® shows a limited 
peritoneal retention, characteristic for liquid agents[4]. Despite several similarities between GP-MS and 
Hyalobarrier® gel, there is one major difference between both treatments. The GP-MS are 
intraperitoneally injected after complete closure of the ventral incision without attempt to direct the 
formulation towards the traumatized areas whereas Hyalobarrier® gel is applied directly in a thin layer 
at the assumed sites of adhesion and stays in place due to its viscous and sticky properties.  
 Other studies reported that Hyalobarrier® was able to reduce adhesions. Binda et al. reported a 
significant reduction of adhesions in Balb/c mice, but the research methodology was different from this 
study since adhesions were laparoscopically induced by hypoxia and normoxia[59], [63], [64]. Efficacy of 
Hyalobarrier® was investigated in a rat uterine horn model[65], [66]. The effect of Hyalobarrier was not yet 
investigated in a standard abraded peritoneal wall-cecum model. This study does not demonstrate a 
significant reduction of adhesion when compared to saline and therefore its efficacy cannot be confirmed 
in this mouse model.  
 Histopathological examination of cecum, abdominal wall and, if applicable, adhesion tissue was 
performed. Generally, cecal serosa and mucosa of GP-MS-treated mice did not display irregularities 
(Suppl. Figure 3a). Visceral adhesions were observed in two GP-MS-treated mice, analysis of cecum 
confirmed mild serositis. Peritoneal tissue had a normal appearance. Local inflammation of mesothelium 
of two GP-MS-treated mice with parietal adhesions was noticed, but there was no infiltration into muscle 
tissue of abdominal wall. Adhesion tissue consisted of adipose tissue with lymphocytic infiltration. 
Cecal serositis was seen in all control mice with no abnormalities of cecal mucosa. Inflammatory cells 
were abundantly present when cecum was adhered to abdominal wall. All control mice showed 
peritonitis with extensive infiltration into muscle tissue of abdominal wall (Suppl. Figure 3b). 
Lymphocytes were observed in adipose tissue of adhesions. Analysis of cecum, peritoneum and 
adhesion tissue of Hyalobarrier-treated mice (Suppl. Figure 3c) showed similar characteristics of 
inflammation as tissues of control mice. In conclusion, histopathological examination confirmed the 
results of scoring of adhesions. GP-MS are able to prevent peritoneal adhesions and thereby recover 
normal histology of cecum and peritoneum. In contrast, mild to severe inflammation of cecal serosa and 
peritoneum was observed in all control and Hyalobarrier-treated mice.     
 Subsequently, cytokines IL-1ß, IL-6 and TNF-, inflammatory markers released during the 
peritoneal adhesions cascade[1], [2], were analysed in plasma and peritoneal fluid. None of the cytokines 
were present in plasma above the limit of detection (55.2 pg/ml for IL-1ß, 58.8 pg/ml for IL 6, 30.5 
pg/ml for TNF-) at any time point (day 1, 7 and 14 post-operative). Cytokine analysis of peritoneal 
fluid (Suppl. Figure 4) illustrated that concentration of IL-1ß, IL-6 and TNF- of control and 
Hyalobarrier-treated mice were slightly higher than GP-MS-treated mice at any time point but without 
significant difference. Cytokines were most abundantly present at day 1 after abrasion of cecum and 
peritoneum. IL-1 and TNF- are produced by activated macrophages in peritoneal fluid and mainly 
important in the early phase of wound healing. Production of IL-6 is up-regulated by IL-1 and TNF-. 
These cytokines interact with the fibrinolytic pathway and influence the remodeling of the extracellular 
matrix which may be responsible for formation of adhesions after peritoneal injury[67]. Concentration of 
cytokines after induction of adhesions was higher for all animals than before induction. It has been 
reported that surgical tissue trauma is followed by a cascade of inflammatory signaling and activation 
of epithelial, endothelial and inflammatory cells, platelets and fibroblasts[68]. Nevertheless, no significant 
difference could be appointed and concentrations of cytokines were around limit of detection. The local 
induction of adhesions could be an explanation for the limited increase of concentration of cytokines, 
while a more extensive and aggressive model of induction of peritoneal adhesions could possibly induce 
a higher increase of cytokines in peritoneal fluid.  
4. Conclusion 
 Spheroid gelatin microspheres were prepared by a modified emulsification solvent extraction 
method. Microspheres were stabilized by crosslinking using genipin. GP-MS did not influence cell 
viability when analysed by MTT assays using SKOV-3 cells. In vivo studies in mice showed excellent 
biocompatibility, distribution and degradation characteristics of GP-MS. GP-MS appear to be a 
promising strategy to prevent postoperative peritoneal adhesions. GP-MS-treated mice developed 
significantly less postsurgical adhesions when compared to saline and Hyalobarrier®-treated animals. 
Future work will include the incorporation of a cytostatic agent into the microspheres. Drug release will 
be monitored in vitro and in vivo. In addition, the potential efficacy of the drug-loaded microspheres 
will be evaluated in a mouse model for peritoneal metastasis of ovarian origin.   
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Figures 
 
Figure 1: Hypothetic subdivision of the abdominal cavity[41]. 
 
Figure 2: Influence of the composition of the emulsion on the size of the gelatin microspheres (n=3; ± SD) 
 
Figure 3: Degree of crosslinking (%) of gelatin microspheres (n=3; ± SD) in function of genipin concentration (0.1, 0.5 1 w/v% genipin) and crosslinking 
time (h) 
 
Figure 4: Photomicrographs of genipin-crosslinked gelatin microspheres after (a) 5h and (b) 24 h of crosslinking using 0.5 w/v % genipin  
 
Figure 5: In vitro enzymatic (collagenase I) degradation of gelatin microspheres (n=3; ±SD) crosslinked using 0.1 w/v % (A) and 0.5 w/v % (B) genipin 
and different crosslinking times 
 
Figure 6: (A) influence of genipin concentration (% w/v) in the reaction medium on cell viability in time measured by MTT assay on SKOV-3 cells (n= 
18, ± SD); (B) influence of concentration of GP-MS on cell viability of SKOV-3 cells in time (n=18, ± SD) 
  
Figure 7: macroscopic images of abdominal cavity of Balb/c mice. Evaluation of distribution pattern of GP-MS 2 days (A), 7 days (B), 14 days (C), 21 
days (D) and 28 days (E) after IP injection. 
 
 
 
Figure 8 : Photographs of the abdominal cavity of control mice after induction of peritoneal adhesions (A) Day 2: type 3 adhesions, qualitative score of 8 
(B) Day 7: type 3 adhesions, qualitative score of 8 (C) Day 14: type 3 adhesions, qualitative score of 9 (vascularised)  
 
 
Figure 9: Photographs of the abdominal cavity of GP-MS-treated mice after induction of peritoneal adhesions (A) Day 2: no adhesions, (B) Day 7: 
formulation almost completely degraded, no adhesions (C) Day 14: formulation entirely degraded, no adhesions  
 
 
Figure 10: Photographs of the abdominal cavity 14 days after induction of peritoneal adhesions. Control mouse: (A) visceral adhesions, (B) parietal 
adhesion, colon attached to peritoneum; Hyalobarrier®-treated mouse: (C) parietal adhesions, cecum attached to peritoneum, (D) 1=visceral adhesion, 
2=parietal adhesion, cecum attached together; GP-MS-treated mouse: (E) no adhesions, normal physiology, (F) filmy adhesion between cecum and greater 
omentum. Arrows indicate peritoneal adhesions.  
Tables 
Table 1: Qualitative adhesion scoring system[40] 
Category Score 
Extent 
-No adhesion 
-1-25% of the peritoneal cavity involved 
-26-50% of the peritoneal cavity  involved 
-51-75% of the peritoneal cavity  involved 
-76-100% of the peritoneal cavity involved 
0 
1 
2 
3 
4 
Type 
-No adhesion 
-Filmy 
-Dense 
-Vascular 
0 
1 
2 
3 
Tenacity 
-No adhesion 
-Easily fall apart 
-Require traction 
-Require sharp dissection 
0 
1 
2 
3 
Total adhesion score (Extent + Type + Tenacity) 0-10 
             
Table 2: Quantitative adhesion scoring system[42]  
Criteria  
Site of adhesions 
Parietal Pelvic fat body-abdominal wall 
Omentum-abdominal wall 
Intestine-abdominal wall 
Visceral Omentum-liver/stomach 
Intestine-intestine 
Liver-stomach 
Tenacity 
Type 0 
Type I 
Type II 
Type III 
No adhesion 
Simple, without dissection 
Dissection needed to separate adherent area 
Dissection needed to cut the adhesions 
Vascularization of adhesions 
Vascularized 
Avascularized 
 
Table 3: The Zühlke grading classification of adhesions[43] 
Grade  Description 
Grade 0 
Grade I 
Grade II 
Grade III 
Grade IV 
No adhesion 
Filmy adhesions that require gently blunt dissection to be divided 
Mild adhesions that require aggressive blunt dissection to be freed 
Moderate adhesions that require sharp dissection to be freed 
Severe adhesions that are not dissectible without damage to adherent organs 
 
 
 
 
Table 4: Influence of surfactants on the size of gelatin microspheres (n=3)  
Surfactant D[4,3] ± SD (µm) (n=3) 
sorbitan esters (Span®) and their ethoxylates (Tween®) 
Tween® 20 147 ± 13 
Tween® 80 84 ± 13 
Tween® 80/Span® 80 71 ± 4 
Tween® 85 119 ± 29 
Span® 85/Tween® 85 110 ± 12 
poloxamers (Pluronic®) 
Pluronic® F68 155± 23 
Pluronic® F127 270 ± 15 
Pluronic® L121 65 ± 11 
polyethoxylated castor oil (Cremophor® RH) 
Cremophor® RH 60 58 ± 10 
 
Table 5:  Degradation time (d) of genipin-crosslinked microspheres (n=3; ±SD) by hydrolysis at 37 °C  
Crosslinking time (h) 5 15 24 48 72 96 
% w/v genipin time needed to degrade the microspheres (d)  
0.1 1.0 ± 0.0 1.0 ± 0.0 2.7 ± 0.6 3.7 ± 0.6 4.3 ± 0.6 8.3 ± 0.6 
0.5 2.0 ± 0.0 7.3 ± 0.6 17.0 ± 1.0 29.0 ± 1.0 37.0 ± 2.0 41.7 ± 2.5 
1.0 4.0 ± 1.0 15.7 ± 1.5 43.3 ± 1.5 51.3 ± 0.6 53.7 ± 1.2 58.7 ± 2.1 
 
Table 6 : Qualitative and quantitative valuation of peritoneal adhesions in GP-MS-treated (n=12; 3 per time 
point) and control mice (n=3; 1 per time point) on post-operative day 2, 7 and 14. 
Post-operative 
day 
 
Quality of adhesions Quantity of adhesions 
GP-MS treated 
mice 
Control mice GP-MS treated 
mice 
Control mice 
Total score Tenacity (Type) 
Day 2 0 8 0 3 
Day 7 0 8 0 3 
Day 14 0 9 0 3 
 
Table 7: Quantitative scoring of adhesions per treatment group (control, Hyalobarrier® and GP-MS 
group) including site of adhesions, tenacity and vascularization. 
Category Control (n=11) Hyalobarrier® (n=11) GP-MS (n=11)  
Site adhesions 
Parietal 
Visceral 
 
7  
11  
 
5 
11 
 
2 
2 
Tenacity 
Type 0 
Type I 
Type II 
Type III 
 
0 
0 
5 
6 
 
0 
0 
3 
8 
 
7 
4 
0 
0 
Vascularization 10 9 1 
 
 
 
 
Table 8: Qualitative scoring of peritoneal adhesions post-operative day 14. Results are displayed as average 
score ± standard deviation per category for each treatment group (n=11). 
Category Control group (n=11) Hyalobarrier® group (n=11) GP-MS group (n=11) 
Extent 
Type 
Tenacity 
2.64 ± 0.92 
2.55 ± 0.69 
2.73 ± 0.47 
3.00 ± 1.10 
2.64 ± 0.47 
2.73 ± 0.47 
0.45 ± 0.69 
0.27 ± 0.47 
0.45 ± 0.69 
Total score 7.91 ± 1.70 8.36 ± 1.91 1.18 ± 1.78 
 
Table 9: Number of mice and total average grade ± SD per adhesion grade according to the Zühkle 
classification per treatment group. 
Grade Control group (n=11) Hyalobarrier® group (n=11) GP-MS group (n=11) 
Grade 0 
Grade I 
Grade II 
Grade III 
Grade IV 
0 
0 
2 
6 
3 
0 
0 
1 
3 
7 
7 
4 
0 
0 
0 
Average 3.09 ± 0.70 3.55 ± 0.69 0.36 ± 0.50 
 
   
Supplementary data 
 
 
Figure 1a: Optical micrographs of H&E-stained slices of tissues of GP-MS-treated mice. (A) cecum, where MI = muscularis, Mu = mucosa, Se = serosa; 
(B) colon, where CrLi = Crypt of Lieberkühn, GoCe= Goblet Cell, MI = muscularis, Mu = mucosa, Se = serosa; (C) Greater Omentum, where A=Adipose 
Tissue; (D) Peritoneum/Abdominal Wall, where Ad=Adipose Tissue, SkM= Skeletal Muscle. Original magnification of 200x (A, C, D) and 400x (B). 
 
Figure 1b: Optical micrographs of H&E-stained slices of tissues of GP-MS-treated mice. (A) Spleen, where RePu = Red Pulp, WhPu = White Pulp; (B) 
Pancreas, where ExPa = Exocrine Pancreas, IsLa = Islet of Langerhans; (C) Liver, where LiPa = Liver Parenchyma, PoVe = Portal Vein; (D) Kidneys, 
where BV = Blood Vessel, Ca = Capsule, CoTu = Convoluted Tubule, Gl = Glomerulus . Original magnification of 100x (A,B,C) and 200x (D). 
 
Figure 2a: Optical micrographs of H&E-stained slices of tissues of mice two days after induction of peritoneal adhesions. Inflammatory cells are observed 
in cecum (A), abdominal wall/peritoneum (B) and adhesion (C) of control mice. Cecum (D) and abdominal wall/peritoneum (E) of GP-MS-treated mice 
also displayed inflammatory cells. Scale bar represents 100 µm. Original magnification of 200x. Ad = adipose tissue, Ly = lymph node, M = muscularis, 
Mu = mucosa, Se = serosa, SkM = skeletal muscle, arrows indicate inflammatory cells. 
 
 
Figure 2b: Optical micrographs of H&E-stained slices of tissues of mice seven days after induction of peritoneal adhesions. Inflammatory cells are 
observed in cecum (A), abdominal wall/peritoneum (B) and adhesion (C) of control mice. Cecum of GP-MS-treated mice (D) displays normal architecture 
and few inflammatory cells are seen at abdominal wall/peritoneum (E) of GP-MS-treated mice. Scale bar represents 100 µm (A-C and E) or 50 µm (D). 
Original magnification of 200x (A-C and E) and 400x (D). Ad = adipose tissue, Ly = lymph node, M = muscularis, Mu = mucosa, Se = serosa, SkM = 
skeletal muscle, arrows indicate inflammatory cells. 
 
 
Figure 2c: Optical micrographs of H&E-stained slices of tissues of mice fourteen days after induction of peritoneal adhesions. Extensive inflammation is 
observed in cecum (A), abdominal wall/peritoneum (B) and adhesion (C) of control mice. Cecum of GP-MS-treated mice (D) displays normal architecture 
and few inflammatory cells are seen at abdominal wall/peritoneum (E) of GP-MS-treated mice. Scale bar represents 100 µm (A-C and E) or 50 µm (D). 
Original magnification of 200x (A-C and E) and 400x (D). Ad = adipose tissue, M = muscularis, Mu = mucosa, SkM = skeletal muscle, arrows indicate 
inflammatory cells 
 
Figure 3a: Optical micrographs of H&E-stained slices of tissues of GP-MS-treated mice two weeks after induction of peritoneal adhesions. Cecum (A) 
and peritoneum/abdominall wall (B)  display normal architecture. Adhesion tissue (C) consists of adipose tissue with inflammatory cells. Original 
magnification of 400x (A), 200x (B), 100x (C). Ad = adipose tissue, Ly = lymphocytes, Me = mesothelium, MI = muscularis, Mu = mucosa, Se = serosa, Sm 
= smooth muscle. 
 
Figure 3b: Optical micrographs of H&E-stained slices of tissues of control mice two weeks after induction of peritoneal adhesions. (A) adhesion formed 
between abdominal wall and cecum. Arrow indicates inflammatory infiltrate. Original magnification of 200x. (B) Massive infiltration of inflammatory 
cells into mesothelium and smooth muscle. (C) Adhesion tissue consisting of adipose cells, connective tissue and inflammatory cells. Original magnification 
of 100x (B and C). Ad = adipose tissue, CoT = connective tissue, Ly = lymphocytes, Mu = mucosa, Sm = smooth muscle. 
 
Figure 3c: Optical micrographs of H&E-stained slices of tissues of Hyalobarrier-treated mice two weeks after induction of peritoneal adhesions. (A) 
adhesion formed between abdominal wall and cecum. (B) Extensive infiltration of inflammatory cells into mesothelium and smooth muscle of abdominal 
wall. (C) Adhesion tissue consisting of adipocytes, connective tissue and presence of inflammatory cells. Original magnification of 100x. Arrow indicates 
inflammatory infiltrate. Ad = adipose tissue, CoT = connective tissue, MI  = muscularis, Mu = mucosa, Sm = smooth muscle. 
  
  
  
Figure 4: Cytokine evaluation of peritoneal fluid of control, Hyalobarrier and GP-MS-treated mice. Concentration of IL 1B (A), IL 6 (B), TNF alpha (C) 
in pg/ml are displayed in function of time (day 1, 7 and 14 post-operative).    
 
 
 
